Content area
Full Text
AstraZeneca has officially opened its new research facility in South San Francisco, bundling five of its Bay Area sites into a single unit at the heart of California’s biotech cluster.
The new location—at the Cove at Oyster Point—is the new workplace for around 400 employees gathered from AZ’s TIDE (Technology Innovation & Delivery Excellence) unit, as well as subsidiaries Acerta Pharma, MedImmune, and Pearl Therapeutics.
There had been speculation that staff from ZS Pharma might also transfer to the new facility, but they were moved along with AZ's renal-cardio therapeutic area from San Mateo in California to Wilmington, Delaware as of January 1 this year.
AZ’s chief medical officer, Sean Bohen, M.D., Ph.D., described the opening as a “milestone” for the company and a “demonstration of our commitment to a strong and visible presence in California.” The new facility...